Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Share-based Compensation (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Share-based Compensation data on record, last reported at $3.9 million in Q4 2021.

  • For Q4 2021, Share-based Compensation rose 344.8% year-over-year to $3.9 million; the TTM value through Dec 2021 reached $11.7 million, up 94.22%, while the annual FY2025 figure was $46.1 million, 15.95% up from the prior year.
  • Share-based Compensation reached $3.9 million in Q4 2021 per COGT's latest filing, up from $3.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.9 million in Q4 2021 and bottomed at $479000.0 in Q1 2018.
  • Average Share-based Compensation over 4 years is $1.5 million, with a median of $868000.0 recorded in 2020.
  • Peak YoY movement for Share-based Compensation: dropped 8.37% in 2019, then skyrocketed 345.69% in 2020.
  • A 4-year view of Share-based Compensation shows it stood at $902000.0 in 2018, then fell by 6.65% to $842000.0 in 2019, then rose by 2.85% to $866000.0 in 2020, then skyrocketed by 344.8% to $3.9 million in 2021.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $3.9 million in Q4 2021, $3.5 million in Q3 2021, and $2.6 million in Q2 2021.